Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

"God asks no man whether he will accept life. That is not the choice. You must take it. The only choice is how."

This is what Justice JB Pardiwala said, quoting Henry Ward Beecher to allow India's first ever passive euthanasia for Harish Rana. AIIMS Delhi has now started protocols to implement the Supreme Court verdict for Harish Rana's passive euthanasia. Sources and several reports have mentioned that the process could take two to three weeks.

How Is AIIMS Delhi Preparing For Passive Euthanasia?

A specialized team headed by professor and head of the department of anesthesia and palliative medicine, Dr Seema Mishra, has been constituted to implement the process. The team comprises doctors from departments of neurosurgery, onco-anesthesia, and palliative medicine, and psychiatry.

“The process generally involves withholding or withdrawing the nutritional support gradually while ensuring adequate pain relief. The patient is given palliative sedation so that he or she is not in distress. Life support measures such as artificial nutrition, oxygen and medications are slowly withdrawn. The aim is not to prolong nor hasten death,” Dr Sushma Bhatnagar, former head of the department of onco-anaesthesia, pain and palliative care, AIIMS-Delhi.

Harish Rana Update

A video from Rana's home in Ghaziabad showed that relatives were offering prayers and a member of the Brahma Kumaris put a 'tilak' on his forehead. She said, "Sabko maaf karte hue, sabse maafi mange hue, so jaao...theek hai." Which loosely translates to: Forgiving everyone and asking forgiveness from everyone. Now sleep. It's okay.

The Brahma Kumari seen in the video was Sister Lovely from Mohan Nagar Seva Kendra in Ghaziabad. Komal, who is also a member of Brahma Kumaris based in Mount Abu, told this to news agency Press Trust of India (PTI). "She is following a ritual with the words that mean he (Harish) leave the world in a happy state, seeking and giving forgiveness...it is part of a meditative chant that comforts the soul and eases the entire process of soul merging with the sublime," she told PTI.

According to Komal, alongside medical consultations, the family also sought spiritual guidance as they prepared for the inevitable after the Supreme Court’s directions.

Read: Harish Rana Case Brings Spotlight On How Passive Euthanasia Has Evolved Over The Years

Harish Rana's Passive Euthanasia

The Supreme Court of India, in a landmark judgment allowed 32-year-old Harish Rana, who had been living in a vegetative state for last 13 years, the right to die. This means, that the apex court allowed passive euthanasia for Rana. The bench comprising Justice JB Pardiwala an Justice KV Vishwanathan allowed the withdrawal of life support of Rana, who has been in a coma and kept alive on tubes for breathing and nutrition after he sustained severe head injuries following a fall from a building in 2013 in Chandigarh.

The judgment is a win, however, Ashok, Rana's father said that his feelings are mixed. "As a father, this is extremely painful. But on humanitarian grounds, this is the best we can do for my son." He continued, "It is just not a matter of my son, but there are many others in such a state in the country. I think it is the grace of God who guided the Supreme Court judges... I am happy that with this judgments, many others may find a way."

Tech giant Microsoft's new artificial intelligence model GigaTIME will help reduce time and cost as well as expand access to cancer care, said CEO Satya Nadella today.

Nadella noted that its multimodal AI system has shown promise in transforming routine pathology slides into detailed spatial proteomics data -- a high-resolution map of proteins.

The advanced technology may help doctors analyze tumors faster, thus bringing hope to millions of cancer patients worldwide for a better and faster diagnosis.

Taking to social media platform X, Nadella said: “We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care”.

What is GigaTIME

GigaTIME is a multimodal AI model for translating routinely available hematoxylin and eosin (H&E) pathology slides to virtual multiplex immunofluorescence (mIF) images.

H&E is the "gold standard" technique in pathology for diagnosing cancer. The mIF images share details of proteins and their locations in cancer cells, thus advancing precision immuno-oncology research.

Developed in collaboration with Providence and the University of Washington, the team trained GigaTIME on a dataset of 40 million cells with paired H&E and mIF images across 21 protein channels.

The multimodal AI, which analyzed standard pathology slides, showed the potential to generate a “virtual population” of tumor cells. It also revealed the detailed protein activity within cancer cells.

The images also offer deeper insights into how tumors behave and disease progression, enabling doctors to cut down the time and cost of diagnosis.

“GigaTIME is about unlocking insights that were previously out of reach,” explained Carlo Bifulco, chief medical officer of Providence Genomics and medical director of cancer genomics and precision oncology at the Providence Cancer Institute, in a Microsoft Blogpost

“By analyzing the tumor microenvironment of thousands of patients, GigaTIME has the potential to accelerate discoveries that will shape the future of precision oncology and improve patient outcomes,” Bifulco added.

How GigaTIME Works

In the paper, detailed in the journal Cell, scientists from Microsoft reported that they applied GigaTIME to 14,256 cancer patients from 51 hospitals and over a thousand clinics.

The AI system generated a virtual population of around 300,000 mIF images spanning 24 cancer types and 306 cancer subtypes.

This virtual population uncovered 1,234 statistically significant associations linking mIF protein activations with key clinical attributes such as biomarkers, staging, and patient survival.

"By translating readily available H&E pathology slides into high-resolution virtual mIF data, GigaTIME provides a novel research framework for exploring precision immuno-oncology through population-scale TIME analysis and discovery," the researchers said.

"The GigaTIME model is publicly available to help accelerate clinical research in precision oncology," they added.

The American College of Cardiology (ACC) and the American Heart Association (AHA) released the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. These guidelines introduce important updates in cardiovascular risk assessment, lipid testing, and lipid-lowering therapy.

The guidelines focus on the cases of young people facing heart issues and thus highlight 10 key actions for 2026, which also includes early detection and starting cholesterol check as early as the age 19.

The guidelines have been published in the March 2026 issue of Circulation. The document was developed by a multidisciplinary panel that presented several organization, including the American Diabetes Association (ADA), National Lipid Association (NLA), and Preventative Cardiovascular Nurses Association (PCNA).

The 2026 guidelines will replace the widely used earlier AHA/ACC 2018 cholesterol guidelines, while incorporate new findings and big clinical trials, which will include lipid biomarkers, and enhanced cardiovascular risk prediction models.

What Are The New Steps Introduced By ACC/AHA 2026 Guidelines?

The focus of the new guidelines is on early detection and lifelong risk reduction. The key 10 actions include:

Read: AHA Cholesterol Guidelines 2026: How Indians Can Improve Heart Health

Early Prevention

One of the biggest shifts in the new recommendations is the focus on early detection and management of lipid disorders, especially among younger people. The aim is to reduce lifetime exposure to atherogenic lipoproteins and prevent the long-term development of atherosclerotic cardiovascular disease (ASCVD).

Use PREVENT For Risk Prediction

The guidelines introduce the PREVENT risk equations to estimate 10-year and 30-year cardiovascular risk in adults aged 30–79. This replaces the earlier pooled cohort equations and is expected to improve how patients are categorized according to risk.

Early Treatment For Borderline-risk Patients

Lipid-lowering therapy can now be considered for primary prevention in individuals with a borderline 10-year ASCVD risk (3–5%). For those with intermediate risk (5–10%), treatment decisions should involve shared discussions between doctors and patients.

LDL-C

The updated guideline reintroduces clear LDL-C and non-HDL-C treatment targets, along with percentage reduction goals. These benchmarks help clinicians decide when to intensify treatment.

ApOB Testing

The recommendations suggest measuring apolipoprotein B (ApoB), particularly in patients with high triglycerides, diabetes, or cases where LDL-C levels may underestimate the number of atherogenic particles.

Adults Must Undergo One-time Lp(a) Testing

Because lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease, the guideline advises that all adults undergo at least one lifetime test to identify inherited cardiovascular risk.

Coronary Calcium Scoring (CAC)

Coronary artery calcium (CAC) scoring can help guide treatment decisions, especially for people with borderline or intermediate cardiovascular risk who are unsure about starting statin therapy.

Lipid Therapy for High Risk Comorbidities

Adults aged 40–75 years with conditions such as diabetes, stage 3–4 chronic kidney disease, or HIV infection should receive lipid-lowering therapy for primary prevention, even if their baseline LDL-C levels are not elevated.

Secondary Prevention Methods

For patients with established ASCVD and high risk, the guideline recommends an LDL-C target below 55 mg/dL, as lower levels are linked to better cardiovascular protection.

Stating - The Cornerstone of Therapy

Despite newer medications, statins continue to be the first-line therapy for most patients with dyslipidemia and play a major role in reducing ASCVD risk. Additional treatments such as ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran may be added depending on treatment goals and patient needs.